Expert Review of Pharmacoeconomics & Outcomes Research · 2015 · 46 citations · 9 references
PharmacyPharmaceutical PolicyDrug Approval ProcessesHealth Technology AssessmentPharmaceutical Procurement PolicyAccess To MedicinesDrug ApprovalEssential MedicinesMedication ProcurementNew Drug ApplicationsPharmaceutical AssessmentAccess To BiosimilarsDrug Launch StrategyDrug PurchasingEntryHealth Technology Assessment StrategyHorizon ShiftingMarket Access For BiosimilarsPharmaceutical Procurement
The 3-day course on the managed introduction of new drugs was organised by the Piperska group together with the Agency for Health Technology Assessment and Tariff System (AOTMiT) and WHO Europe to share experiences and case histories among health authority and health insurance company personnel, academics and those from commercial organisations from across Europe on potential ways to optimise the managed entry of new medicines. This starts pre-launch with horizon scanning and budgeting, then peri-launch including critical drug evaluation, and finally post launch including monitoring prescribing of new medicines against agreed guidance and indicators. There were also discussions on issues regarding managed entry schemes and procurement strategies including biosimilars.
9
Priority medicines for Europe and the world
Warren Kaplan, Richard Laing, Bruce Neal · 2004 · 240 citations
Lars L. Gustafsson, Björn Wettermark, Brian Godman et al. · Basic & Clinical Pharmacology & Toxicology · 2011 · 226 citations